Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations

被引:32
作者
Kim, IJ
Kang, HC
Jang, SG
Kim, K
Ahn, SA
Yoon, HJ
Yoon, SN
Park, JG [1 ]
机构
[1] Korean Hereditary Tumor Registry, Canc Res Inst, Seoul, South Korea
[2] Seoul Natl Univ, Canc Res Ctr, Seoul, South Korea
[3] Natl Canc Ctr, Res Inst Hosp, Goyang 411769, Gyeonggi, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea
关键词
D O I
10.1093/carcin/bgi237
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Various types of human cancers harbor BRAF somatic mutations, leading researchers to seek molecular targets for BRAF inhibitors. A mutually exclusive relationship has been observed between the BRAF-V600E mutation and K-ras mutations, suggesting that the BRAF-V600E mutation may differ from the other BRAF mutant types. Here, we used microarray analysis to examine differences between the BRAF and K-ras mutant colorectal samples and within the BRAF group (V600E versus non-V600E), in the hope that the identified gene sets could form the basis for new target development. Eleven colorectal cancers (CRCs) with BRAF mutations and nine with K-ras mutations were examined by high-density microarray analysis. We also tested whether other significant genetic or clinical status involved in CRC development, such as APC and TP53 mutations, MSI and TNM-Duke's staging, were related with the observed BRAF- or K-ras associated expression profiles. Unsupervised two-way hierarchical clustering and multidimensional scaling revealed that the differentially expressed genes clustered according to the mutation status of BRAF and K-ras, and that samples with the BRAF-V600E and non-V600E mutants could be distinguished from each other by gene profiling. Examination of TNM-Duke's staging, MSI and mutations in APC and TP53 revealed that these significant mutations could not account for the hierarchical clustering results observed in our study. We herein identified distinct gene expression patterns and gene sets that may form the basis for identification of BRAF-targeting molecules or provide researchers with a better understanding of the molecular pathogenesis underlying RAS-RAF signaling.
引用
收藏
页码:392 / 404
页数:13
相关论文
共 55 条
[1]  
Bakkar AA, 2003, CANCER RES, V63, P8108
[2]   Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity [J].
Banerjea, Ayan ;
Ahmed, Shafi ;
Hands, Rebecca E. ;
Huang, Fei ;
Han, Xia ;
Shaw, Peter M. ;
Feakins, Roger ;
Bustin, Stephen A. ;
Dorudi, Sina .
MOLECULAR CANCER, 2004, 3 (1)
[3]   MUTATION IN THE DNA MISMATCH REPAIR GENE HOMOLOG HMLH1 IS ASSOCIATED WITH HEREDITARY NONPOLYPOSIS COLON-CANCER [J].
BRONNER, CE ;
BAKER, SM ;
MORRISON, PT ;
WARREN, G ;
SMITH, LG ;
LESCOE, MK ;
KANE, M ;
EARABINO, C ;
LIPFORD, J ;
LINDBLOM, A ;
TANNERGARD, P ;
BOLLAG, RJ ;
GODWIN, AR ;
WARD, DC ;
NORDENSKJOLD, M ;
FISHEL, R ;
KOLODNER, R ;
LISKAY, RM .
NATURE, 1994, 368 (6468) :258-261
[4]   Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group Report [J].
Coudert, B ;
Anthoney, A ;
Fiedler, W ;
Droz, JP ;
Dieras, V ;
Borner, M ;
Smyth, JF ;
Morant, R ;
de Vries, MJ ;
Roelvink, M ;
Fumoleau, P .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (17) :2194-2198
[5]  
Cripps MC, 2002, CLIN CANCER RES, V8, P2188
[6]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[7]   BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer [J].
Deng, GR ;
Bell, I ;
Crawley, S ;
Gum, J ;
Terdiman, JP ;
Allen, BA ;
Truta, B ;
Sleisenger, MH ;
Kim, YS .
CLINICAL CANCER RESEARCH, 2004, 10 (01) :191-195
[8]  
DeRisi J, 1996, NAT GENET, V14, P457
[9]   BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing [J].
Domingo, E ;
Laiho, P ;
Ollikainen, M ;
Pinto, M ;
Wang, L ;
French, AJ ;
Westra, J ;
Frebourg, T ;
Espín, E ;
Armengol, M ;
Hamelin, R ;
Yamamoto, H ;
Hofstra, RMW ;
Seruca, R ;
Lindblom, A ;
Peltomäki, P ;
Thibodeau, SN ;
Aaltonen, LA ;
Schwartz, S .
JOURNAL OF MEDICAL GENETICS, 2004, 41 (09) :664-668
[10]   Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization [J].
Dunican, DS ;
McWilliam, P ;
Tighe, O ;
Pale-McDermott, A ;
Croke, DT .
ONCOGENE, 2002, 21 (20) :3253-3257